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Probing the epigenetic regulation of HIF-1a
transcription in developing tissue
I. N. Mistry,a P. J. S. Smith,b D. I. Wilsonc and A. Tavassoli*ab
HIF-1 is the master regulator of cellular hypoxia response; the oxygen sensitive HIF-1a subunit
transactivates its own expression in hypoxia via a hypoxia response element (HRE) in the promoter of the
HIF-1a gene. This transactivation loop significantly contributes to the build up of HIF-1a at the onset of
hypoxia, with the binding of HIF-1 to the HIF-1a promoter being dependent on the epigenetic status of a
CpG dinucleotide in the upstream HRE. Given the central role played by HIF-1 in tissue development, we
sought to probe the epigenetic status of the HIF-1a HRE and that of its downstream target EPO in
embryonic tissue. Our data shows that the CpG dinucleotide in HIF-1a HRE is unmethylated in several
embryonic tissue samples, suggesting that transactivation of HIF-1a plays a significant role in HIF-1
mediated hypoxia response during development.
Introduction
Homeostasis of oxygen is critical for function and survival of
mammalian cells. Low cellular oxygen, known as hypoxia,
triggers a transcriptional response mediated through hypoxia
inducible factor 1 (HIF-1), a heterodimeric transcription factor
made up of HIF-1a and HIF-1b.1 Both HIF-1 subunits are
constitutively expressed, but HIF-1a is regulated by oxygen; in
normoxia prolyl hydroxylase domain enzymes (PHDs) hydroxylate
HIF-1a, using molecular oxygen as a substrate, which targets it for
ubiquitination and proteasomal degradation.2–4 In hypoxia the
lack of oxygen becomes rate limiting for PHDs, resulting in HIF-1a
stabilization, accumulation, and translocation to the nucleus.5
HIF-1a dimerises with HIF-1b in the nucleus to form the HIF-1
transcriptional complex. HIF-1 binds to the core region (50-RCGTG-
30, where R is A or G) of a 50 base pair hypoxia-responsive element
(HRE) in the promoter or enhancer regions of over 300 target genes,
recruiting co-activators to initiate/upregulate their transcription.6–8
The HIF-1 mediated transcriptional response rapidly follows the
onset of hypoxia,9,10 activating an array of genes that allow cellular
adaptation and survival in low oxygen conditions. HIF-1 plays a
critical role in the growth and survival of tumours by inducing
genes involved in angiogenesis, oxygen transport, invasion and
metastasis.11,12 Hypoxia is often associated with tumorigenesis
and cancer, however development of the mammalian embryo
takes place in a low oxygen environment and in this context,
HIF-signalling plays a significant role. HIF co-ordinates the
development of the blood, vasculature and nervous system, and
affects the morphogenesis of the embryo and placenta.13,14
HIF-1a expression and activity is controlled at the transcription,
translation and post-translation levels, and there is increasing
evidence that epigenetic changes, particularly CpG methylation,
are also key determinants of hypoxia-response. The methylation
state of a CpG dinucleotide in the upstream promoter of HIF-1a
for example, has been recently found to correlate with the rate of
HIF-1a accumulation in hypoxic cancer cells.15,16 This is due to the
presence of an HRE within a CpG island in the promoter region of
the HIF-1a gene (ACGTG, 156 bases upstream from the transcrip-
tion start site),7 which results in the transactivation of HIF-1a
transcription by the HIF-1 transcription factor at the onset of
hypoxia (Fig. 1A).15,16 This results in a significantly accelerated rise
in HIF-1a at both the mRNA and protein level, which in turn
increases the transcription of other HIF-1 target genes; methylation
of this CpG dinucleotide has been shown to inhibit HIF-1 binding
(in vitro and in cells).15,16 The HRE-dependent transcription of
several HIF-1 target genes (e.g. erythropoietin (EPO) and glucose
transporter 3) has also been shown to be regulated by a similar
mechanism,17,18 suggesting a wider role for epigenetic control of
HIF-mediated transcription in hypoxia. The epigenetic status of the
HIF-1aHRE in various cell and tissue types has been little explored,
despite its potential significance for determining the extent of
hypoxia response. A recent study has found HIF-1a mRNA expres-
sion to be exceptionally low in HMC-1 cells, a model immature
mast cell line.19 In vitromethylation of the HIF-1a promoter caused
a significant decrease in reporter gene expression whereas treat-
ment with the DNA demethylating agent 50-azacytidine resulted in
a dose dependent increase in expression of the gene, suggesting the
low expression of HIF-1a in the HMC-1 cells was caused by a
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methylated HIF-1a promoter.19 Given the important role played by
HIF-1 in embryonic development, and the potential significance of
the HIF-1a transactivation loop in controlling hypoxia response,
we hypothesised that the need for rapid hypoxia response in
developing tissue would require an unmethylated HIF-1a HRE. As
the default epigenetic status of the HIF-1a HRE during various
stages of development is currently unknown, we sought to assess
the methylation status of the HIF-1aHRE in developing embryonic
tissue.
Results and discussion
The HIF-1a HRE is unmethylated in embryonic DNA
Primers were designed, using MethPrimer software,20 to
amplify the promoter region of HIF-1a from bisulfite-treated
chromosomal DNA, regardless of methylation status. We began
by validating our epigenetic sequencing method using DNA
extracted from cancer cell lines. MCF-7 breast cancer cells,
which are known to have an unmethylated HIF-a HRE,21 were
used as a negative control. HCT-116 colon cancer cells, which
are known to have a methylated HIF-1a HRE, were used as a
positive control.16 A 220 bp region of the HIF-1a promoter
containing 16 CpG sites (Fig. 1B), including the one within the
HIF-1a HRE (ACGTG) was analysed by bisulphite sequencing.
The sequencing data verified that the cytosine residues in CpG
dinucleotides in the HIF-1a promoter region, and particularly
the cytosine residue in the HIF-1a HRE, were unmethylated in
MCF7s, and methylated in HCT-116s (Fig. 1C).
We next applied this technique to embryonic DNA, isolated
from 7 tissue types (bowel, brain, kidney, stomach, muscle,
adrenal, lung or tongue). These samples were from 4 embryos
55–59 days post conception. No major epigenetic events are
known to take place in this period of development,22 allowing a
comparable view of the methylation status of the HIF-1a
promoter. The methylation status of these DNA samples was
determined by bisulfite sequencing with the above primers.
We found the CpG island region of the HIF-1a promoter to
be largely unmethylated (Fig. 2A). We observed that on average,
1.1% of CpGs were methylated with no more than 2% methylation
in each tissue (Fig. 2C). There was greater variation in the proportion
of methylated CpGs at each position of the HIF-1a promoter
(Fig. 2B), with a maximum of 3.8% methylation at position
146 bp and 3.1% methylation at position 241 bp (both
relative to the HIF-1a TSS). However large errors on these values
show that methylation percentages at these positions are likely
being positively skewed by few highly methylated samples, and that
they are not significantly diﬀerent to unmethylated positions.
The CpG site in the HIF-1a HRE, 155 bp upstream of the
HIF-1a transcription start site (Fig. 1B and 2A, boxed), was
unmethylated in 99% of clones sequenced. Histoimmuno-
chemical analysis of mouse embryos, using the hypoxia marker
pimonidazole and its associated antibody, have shown that
hypoxic cells are widespread in the early stages of embryo
development, and that these hypoxic regions co-localize with
HIF expression.23,24 This data suggests that the HIF-1a trans-
activation loop is active in embryonic tissue, with the HIF-1
transcription factor able to bind to the unmethylated HRE and
upregulate expression of HIF-1a. Previous chromatin immuno-
precipitation assays with HCT-116 cells have shown that HIF-1
is only recruited to an unmethylated HIF-1a promoter, and HIF-
1 does not bind to the HIF-1a promoter when it is methylated.16
Binding of HIF-1 to the HIF-1aHRE amplifies the extent of HIF-
1 mediated hypoxia signaling by upregulating HIF-1a transcription.
The downstream eﬀect of this will be an increase in the rate of
hypoxic transcription of HIF-1 target genes, such as those involved
in vasculogenesis, erythropoiesis and angiogenesis, by HIF-1.13
Analysis of the methylation status of the EPO HRE in
embryonic DNA
To evaluate whether the unmethylated status of the HIF-1a
promoter was a reflection of global demethylation of HREs, we
analysed the methylation status of EPO, another target of HIF-1.
The gene encoding EPO resides on chromosome 7, whereas the
HIF-1a gene resides on chromosome 14. The 30 enhancer of
EPO lacks a CpG island,17 but previous studies have shown that
hypermethylation in the 30 enhancer region leads to a decrease
in EPO expression in primary cancer cell lines, as an unmethylated
EPO HRE is required for HIF-1 binding.17,25 We therefore
determined the methylation status of the 6 CpG dinucleotides
in the EPO enhancer element in embryonic DNA samples by
bisulphite sequencing (Fig. 3A). It should be noted that the same
bisulphite treated DNA used in the HIF-1a study was used for
Fig. 1 Analysis of the methylation status of the HIF-1a promoter via bisulphite sequencing. (A) The HIF-1a transactivation loop. (B) Graphical
representation of the position of the region of the HIF-1a promoter analysed and the 16 CpG sites within this region. Numbers represent position (in
base pairs) relative to the HIF-1a TSS. (C) Methylation status of this region in DNA extracted from MCF7 and HCT116 cell lines. Methylation status of each
CpG site is represented by circles, where white is unmethylated and black is methylated. He CpG situated in the HIF-1a HRE is highlighted.
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evaluation of EPO to ensure consistency between the analysis of
the two genes.
In contrast to the HIF-1a promoter, we observed a high
degree of methylation in the EPO enhancer, with 47% methylation
across all CpG sites (Fig. 3A). It may therefore be concluded that the
unmethylated state of the HIF-1a promoter is not indicative of
global demethylation, but a result of specific epigenetic regulation
in that region. Interestingly, there were significant diﬀerences
(ranging between 21% and 63%) in the methylation state of
individual CpG sites within the EPO enhancer for each tissue,
and between tissues (Fig. 3B). The CpG position situated within the
HRE of EPO had the lowest average methylation in the locus
studied; only 21%, compared to the average 47%, this value was
significantly lower than other EPO CpG sites, except for the site
adjacent to the EPO HRE (97 bp downstream from the EPO 30
polyadenylation site). The relative lack of methylation of the CpG
site in the EPO HRE indicates that despite methylation of the
enhancer region, binding of HIF-1 and transcriptional activation of
EPO can still occur in these tissues. Previous studies have shown
that methylation of the CpG residue within the core HRE (ACGTG)
alone prevents binding of HIF-1 to the EPO enhancer region,17
indicating the importance of HRE DNA methylation in dictating
HIF-1 association with DNA. The level of methylation in the EPO
enhancer varied between tissues from 29% in tongue to 65% in
stomach (Fig. 3C). This disparity between tissues may be a result of
diﬀering degrees of hypoxia throughout the developing embryo.
For example, areas of low oxygen are more consistently detected in
specific regions of the embryo such as the developing heart, gut
and skeleton.13,26 This is likely due the significant growth and
energy demands of these tissues.13 While the molecular basis of
Fig. 2 Analysis of the methylation status of the HIF-1a HRE in DNA extracted from embryonic tissue. (A) Methylation status of each CpG site represented
by circles, where white is unmethylated and black is methylated. The CpG situated in the HIF-1a HRE is highlighted. Each row represents data from one
sequenced clone, which are grouped by tissue: adrenal, bowel, brain, kidney, lung, muscle, stomach and tongue. 5 clones of each DNA sample were
sequenced. Scale bar shows position (bp) relative to the HIF-1a TSS. (B) Percentage methylation of above CpG sites grouped by CpG position, bars
represent mean proportion of methylated clones at each position  SEM. (C) Percentage methylation of above CpG sites by tissue, bars represent mean
proportion of methylated clones in each tissue  SEM.
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such selective demethylation events are not clear, the increased
methylation in the region as a whole may dampen transcriptional
activation by recruiting methyl binding proteins and histone
deacetylases, exemplifying the complexity of the interlinking
epigenetic mechanisms of gene regulation.25
Comparison of the above with the methylation status of
the HIF-1a HRE in normal adult tissue would allow a better
understanding of the relevance of HIF-1a HRE demethylation
and the role of the HIF-1a transactivation loop during development.
However, only a few examples of such data could be found in the
literature. The HIF-1a promoter has been shown to be unmethylated
in histopathologically unchanged colon tissue27 and normal uterine
cervical tissue.28 Interestingly, both these studies revealed that,
despite the presence of an unmethylated HRE, HIF-1a mRNA and
Fig. 3 Analysis of the methylation status of the EPO enhancer element by bisulphite sequencing. (A) Graphical representation of the region of the EPO
enhancer analysed, and the 6 CpG sites within this region followed by the methylation status of each CpG site represented by circles, where white is
unmethylated and black is methylated. The CpG situated in the EPO HRE is highlighted. Each row represents data from one sequenced clone, which are
grouped by tissue: adrenal, bowel, brain, kidney, lung, muscle, stomach and tongue; 5 clones of each DNA sample were sequenced. Scale bar shows
position (bp) relative to the EPO 30 polyadenylation site. (B) Percentage methylation of all CpG sites grouped by CpG position, bars represent mean
proportion of methylated clones at each position  SEM. (C) Percentage methylation of all CpG sites grouped by tissue, bars represent mean proportion
of methylated clones in each tissue  SEM.
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protein expression was low in these normal tissues and upregulated
in equivalent cancerous tissue.27,28 These findings underline the
importance of post-translational regulation in regulating intracellu-
lar HIF-1a levels, and suggest that theremay be selective pressure for
the HRE CpG site to remain unmethylated to enable more rapid
recovery of oxygen homeostasis at the onset of hypoxia, indepen-
dently of HIF-1a expression. Selective pressure for an unmethylated
HRE independent of gene expression levels was similarly suggested
for the EPO HRE, where hypomethylation of the EPO HRE was
found in human cell lines and mouse tissues that do not express
EPO.17
Conclusions
There is increasing evidence that HIF-1a expression varies in
diﬀerent tissues and cell types, and that this variation may be
mediated by DNA methylation of the gene promoter.15,16,19 Our
data elucidates the unmethylated status of the HIF-1a HRE in
embryonic DNA samples from various tissues, indicating that
this gene is available for rapid transactivation in the hypoxic
conditions of embryonic development. In addition, we show that
the enhancer region of EPO has a varying degree of methylation
between tissues but a consistently low level of methylation at the
CpG site within its HRE, suggesting additional regulation of EPO
expression. These results give insight into the transcriptional
regulation of HIF-1a and its target EPO in developing tissue.
Experimental
Cell culture
MCF-7 breast carcinoma cells were maintained in DMEM (Life
Technologies) containing 10% FBS. HCT-116 colon carcinoma
cells were maintained in Mcoys’s 5A medium (Life Technologies)
containing 10% FBS. Both cell lines were cultured at 37 1C in 5%
CO2.
Extraction of DNA from cancer cell lines
Confluent MCF-7 and HCT-116 cells were collected by trypinisation
and the cell pellet washed with PBS. The cells were lysed and
genomic DNA extracted using GenEluteMammalian Genomic DNA
miniprep kit (Sigma Aldrich).
Tissue collection and DNA extraction
Embryonic tissue was obtained from women undergoing termina-
tion of pregnancy with written informed consent and ethical
approval. (Southampton & South West Hampshire Local Research
Ethics Committee 296/00). Developmental staging was determined
by foot length and Carnegie staging. DNA was extracted from tissues
as previously described.29
Bisulphite sequencing
Extracted DNA was treated with sodium bisulphite under basic
conditions with Imprint DNA modification kit (Sigma Aldrich)
and the region of interested amplified with universal primers
50-tgatgtatgtttgggattaggtaat-3 and 50-ctctcaaccaatcaaaaaac-30 for
HIF-1a and 50-tggtagtagtgtagtaggtttaggtt-3 0 and 50-aaataaaacca
ccttattaaccaac-30 for EPO with Platinum Taq DNA polymerase
(Life Technologies). The amplified sequences were then TA
cloned into pGEM-EasyT vectors (Promega), transformed into
E. coli. and positive clones were identified by blue/white screen-
ing. Five clones of each DNA sample were sequenced.
Data analysis
The sequencing data file for each clone was aligned and analysed
by BiQ analyser.30 Sequences with a bisulphite conversion rate of
less than 95% were discounted, as were erroneous sequencing
and sequences likely to come from the chromosome of the same
cell. Sequences were grouped by tissue or position and the mean
proportion of methylated CpGs per 5 clones of the same sample
was calculated; unpaired t-tests were used to compare mean
values and determine statistical significance.
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